Hey Emmitt, I don't think anyone answered your question,

New Post Public Reply Private Reply Replies (1) Message Board
Respert24 Emmitt #112881
774
Hey Emmitt,

I don't think anyone answered your question, and as our board's number 2 science guy behind TonyCorvette, I figured I'd give you a quick answer.

You seem to be mashing up how a drug is delivered with whether or not the FDA allows it to be a prescription medicine or not. They're only related in that many drugs delivered in pills are currently offered over the counter. But there are also transdermal patches, nasal sprays, and syrups offered over the counter. There are also drugs offered without prescription that have some decent potential for abuse, like the ephedrine/pseudoephedrine in allergy meds that get used to make meth.

Eventually, a drug like LL should become easier to get and much, much cheaper. But while that would be great for any of us who could benefit from having it with a quick trip to CVS and no prescription, the reality is that we'd make no money from our investment if LL wasn't first a prescription drug that was offered through our country's current physician-insurance framework.

It takes hundreds of millions, if not billions, along with many years of research and development efforts to get a drug to market and the best way to make that money back, and make a bunch of money to fund future indications/products, is to sell it at $8,000/treatment (or whatever) through insurance. The patient still typically pays only a reasonable amount but insurance or a government covers the rest. Cytodyn makes a bunch and smartly reinvests it, the stock goes through the roof, we all make f-you money, and then as patent life extensions finally wear thin it'll be available to the world in an easier and cheaper way.

But along the way we'll have LL Extended Release, LL Respimat Inhaler, LL syrup, LL for Lefties, LL+CBD Gummies, and a variety of other versions that allow us to extend our exclusivity.

There also remains a good reason to first bring a drug through the FDA's process and our current insurance model of healthcare. The FDA approval is both a rubber stamp that it's "safe" and also a way to ensure things are manufactured, marketed, and taken in a safe and trackable way. You won't have some shady company based in India (a huge generics market) making knockoff LL that has no active ingredient or contains filler compounds that are carcinogenic because they aren't regulated. We get regulation surrounding our drug (all drugs) and then as time goes one many of them can transition to over the counter when they're deemed safe and capable of being left in the hands of our unwashed masses. You have to be careful so dumbasses like justa on the other board don't accidentally overdose or kill themselves trying to make meth out of it.

In the end it still costs a good bit and requires highly technical capabilities to make LL, so I don't know if we'll ever see it priced and available like aspirin. But it should absolutely become less expensive and easier to get in the future. After we've all sprained our necks diving into our gold coins like Scrooge McDuck. Hmm, I wonder if LL can help a sprained neck muscle...

I hope that helps.

Respert

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Microplastics Webinar: Navigating Complex Regulations

Updated Category News Views 7

Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...

Continue Reading
New Podcast by Paralyzed Veterans of America Offers Unique Insights

Updated Category News Views 6

Empowering Veterans Through Storytelling Some stories don't just rattle around in your headphones—they stick with you. The 'Voices of PVA' podcast, launched by Paralyzed Veterans of America, aims to do exactly that. It's not just a podcast; it's a platform where voices of veterans and people with spinal cord injuries like MS and ALS aren't just heard, they're amplified....

Continue Reading
Lincoln Educational Services Faces Securities Fraud Suit

Updated Category News Views 4

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

Continue Reading
illycaffè's B Corp™ Recertification Reflects Bold Commitment

Updated Category News Views 6

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Continue Reading
Rise Treatment Center Launches in Vegas for Teens

Updated Category News Views 6

Las Vegas Debuts Rise Adolescent Treatment Center Imagine being a parent in Las Vegas, staring at the daunting task of finding genuine help for your teenage kid just entering those rebellious years. The choices usually feel sparse and lacking. But on August 13, 2026, a shimmer of hope illuminated the landscape with the opening of Rise Adolescent Treatment Center. It’s a...

Continue Reading
NORD Honors Innovators Shaping Rare Disease Treatment

Updated Category News Views 9

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Continue Reading
Brands Must Choose: Cost or Value Leadership?

Updated Category News Views 6

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Continue Reading
NSF Backs New Space Projects: Cooling & Drug Delivery

Updated Category News Views 7

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

Continue Reading
Dr. David Lifschutz Honored for Psychiatry Innovation

Updated Category News Views 7

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

Continue Reading
Starr Conspiracy Unveils AI Tool for B2B Tech Firms

Updated Category News Views 6

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Continue Reading

Top 5 Most Recently Viewed Articles

Credo Technology Sees Growth Surge, Financials Impress Market

Updated Category News Views 204

Strong Earnings Report from Credo Technology Group Credo Technology Group Holding Ltd. (NASDAQ: CRDO) recently announced its fiscal third-quarter earnings, revealing impressive growth that has excited investors. The results were shared following the close of trading on a Tuesday, showcasing the company's remarkable progress in a competitive market. Financial Highlights...

Continue Reading
Lucky Dog Channel Makes a Splash on Xumo Play with Exciting Features

Updated Category News Views 268

Exciting Launch of the Lucky Dog Channel Collaboration Highlighted by Original Episodes and Unique Sponsorship Opportunities Hearst Media Production Group (HMPG) and Xumo, the joint venture streaming platform created by Comcast and Charter, proudly announce the exclusive launch of the Lucky Dog Channel on Xumo Play. Engaging Content for Pet Lovers The Lucky Dog Channel...

Continue Reading
JPMorgan Chase Welcomes Brad D. Smith to Its Board of Directors

Updated Category News Views 117

Brad D. Smith Joins JPMorgan Chase's Board of Directors JPMorgan Chase (NYSE: JPM) has taken a significant step by announcing the election of Brad D. Smith to its Board of Directors. This decision marks a pivotal moment for the company, as it continues to strengthen its leadership team with experienced visionaries. Smith's Background and Experience At 60, Brad D. Smith...

Continue Reading
Shareholder Rights Investigations for MRNS, VCSA, and MHLD

Updated Category News Views 235

Investigation into Shareholder Rights by Halper Sadeh LLC Halper Sadeh LLC, a distinguished law firm specializing in investor rights, is actively examining several companies for possible violations of federal securities laws and fiduciary duties to their shareholders. This investigation particularly focuses on Marinus Pharmaceuticals, Vacasa, and Maiden Holdings,...

Continue Reading
KBRA Offers Insights on the Newest RCKT Mortgage Trust Rating

Updated Category News Views 133

Insights into RCKT Mortgage Trust 2024-CES9 Ratings KBRA, a recognized name in credit ratings, has assigned preliminary ratings to several classes of mortgage-backed notes from the RCKT Mortgage Trust 2024-CES9. This is an important development in the marketplace, especially for those tracking mortgage-backed securities and their related transactions. This RMBS...

Continue Reading